H. Thierry, Chimie organique

J. Olivier, Toxicologie, sécurité sanitaire

K. Francine, Pharmacie galénique

L. Alexandrine, B. Informatique, and M. Faten, Hématologie biologique

M. Christophe, Microbiologie environnementale et moléculaire

M. Blandine, Pharmacognosie

M. Maxime, Pharmacochimie supramoléculaire

P. Francine, Informatique
URL : https://hal.archives-ouvertes.fr/halshs-00345414

P. Christine, Chimie organique

P. Caroline, Pharmacologie

P. Virginie, Biophysique

S. Anne, Pharmacie galénique

T. Nathalie, Santé publique

T. Gabriel, Pharmacologie

V. Marie-noëlle, Biodiversité végétale et fongique

Z. Colette, Pharmacie galénique PROFESSEUR ASSOCIE

M. Anne, Sémiologie 4. Fabrication, p.58

P. Alzari, M. Lascombe, and R. Poljak, Three-Dimensional Structure of Antibodies, Annual Review of Immunology, vol.6, issue.1, pp.555-580, 1988.
DOI : 10.1146/annurev.iy.06.040188.003011

R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1634, 2008.
DOI : 10.1200/JCO.2007.14.7116

S. Benvenuti, A. Sartore-bianchi, D. Nicolantonio, F. Zanon, C. Moroni et al., Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies, Cancer Research, vol.67, issue.6, pp.2643-2648, 2007.
DOI : 10.1158/0008-5472.CAN-06-4158

F. Bibeau, E. Lopez-crapez, D. Fiore, F. Thezenas, S. Ychou et al., Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan, Journal of Clinical Oncology, vol.27, issue.7, pp.1122-1129, 2009.
DOI : 10.1200/JCO.2008.18.0463

F. Bibeau, H. Frugier, A. Denouel, J. Sabourin, and F. Boissiere-michot, Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view, Bull Cancer, vol.96, pp.15-22, 2009.

H. Blons and P. Laurent-puig, Aspect technique de la détermination du statut KRAS dans le cancer colorectal et mise en place en France, Bull Cancer, vol.96, pp.47-55, 2009.

K. Busam, P. Capodieci, and R. Motzer, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, British Journal of Dermatology, vol.11, issue.6, pp.1169-1176, 2001.
DOI : 10.1046/j.1365-2133.1999.02883.x

F. Ciardiello and G. Tortora, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, vol.7, pp.2958-2970, 2001.

K. Chung, J. Shia, N. Kemeny, M. Shah, G. Schwartz et al., Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1813, 2005.
DOI : 10.1200/JCO.2005.08.037

D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg et al., Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004.
DOI : 10.1056/NEJMoa033025

A. F. Esser, Big MAC attack: complement proteins cause leaky patches, Immunology Today, vol.12, issue.9, pp.316-318, 1991.
DOI : 10.1016/0167-5699(91)90006-F

J. Faivre and V. Dancourt, Le dépistage du cancer colorectal certitudes et questions, Gastroenterol Clin Biol, vol.26, pp.86-93, 2002.

M. Frattini, P. Saletti, E. Romagnani, V. Martin, F. Molinari et al., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients, British Journal of Cancer, vol.24, issue.8, pp.1139-1145, 2007.
DOI : 10.1016/j.ctrv.2003.10.003

M. S. Gentile, C. Vasu, A. Green, G. Murillo, D. Gupta et al., Targeting colon cancer cells with genistein-17.1A immunoconjugate, International Journal of Oncology, vol.22, pp.955-959, 2003.
DOI : 10.3892/ijo.22.5.955

S. Grandjouan, Surveillance of very high-risk subjects (polyposis, hereditary nonpolyposis colorectal cancer), Acta Endoscopica, vol.188, issue.4, pp.633-654, 2002.
DOI : 10.1056/NEJM199503303321302

I. Guldenfels, S. Briançon, O. Houot, B. Junod, and J. Deschamps, Comparaci??n de la relati??n costo/eficacia de dos test de despistage de tumores colorectales en un centro de ex??menes de salud, Acta Endoscopica, vol.14, issue.1, pp.27-32, 1990.
DOI : 10.1016/0016-5085(87)90018-7

R. Herbst and D. Shin, Monoclonal antibodies to target epidermal growth factor receptor-positive tumors, Cancer, vol.32, issue.5, pp.1593-1611, 2002.
DOI : 10.1016/0959-8049(95)00592-7

C. Hill and F. Doyon, The frequency of cancer in France: mortality trends since 1950 and summary of the report on the causes of cancer, Bull Cancer, vol.95, pp.5-10, 2008.

F. Hirsch, M. Varella-garcia, P. Bunn, D. Maria, M. Veve et al., Epidermal Growth Factor Receptor in Non???Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, Journal of Clinical Oncology, vol.21, issue.20, pp.3798-807, 2003.
DOI : 10.1200/JCO.2003.11.069

B. Jacobs, D. Roock, W. Piessevaux, and H. , Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.27, issue.30, pp.5068-5074, 2009.
DOI : 10.1200/JCO.2008.21.3744

M. Jost, C. Kari, and U. Rodeck, The EGF receptor-an essential regulator of multiple epidermal functions, Eur J Dermatol, vol.10, pp.505-510, 2000.

S. Khambata-ford, C. Garrett, N. Meropol, M. Basik, C. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

L. Lanier and J. H. Phillips, Evidence for three types of human cytotoxic lymphocyte, Immunology Today, vol.7, issue.5, p.132, 1986.
DOI : 10.1016/0167-5699(86)90076-9

T. Lecomte, Les polyposes coliques: r??le de l???endoscopie et de la chromoendoscopie Pour quels patients demander un conseil g??n??tique ?, Acta Endoscopica, vol.55, issue.4, pp.473-474, 2006.
DOI : 10.1136/gut.2005.082990

A. Lièvre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008.
DOI : 10.1200/JCO.2007.12.5906

J. Mandel, T. Church, J. Bond, F. Ederer, M. Geisser et al., The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer, New England Journal of Medicine, vol.343, issue.22, pp.1603-1607, 2000.
DOI : 10.1056/NEJM200011303432203

Y. Miyakura, K. Sugano, F. Konishi, A. Ichikawa, M. Maekawa et al., Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability, Gastroenterology, vol.121, issue.6, pp.1300-1309, 2001.
DOI : 10.1053/gast.2001.29616

D. Moscatello, M. Holgado-madruga, D. Emlet, R. Montgomery, and A. Wong, Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor, Journal of Biological Chemistry, vol.13, issue.1, pp.200-206, 1998.
DOI : 10.1074/jbc.272.1.154

J. Novotny and K. Sharp, Electrostatic fields in antibodies and antibody/antigen complexes, Progress in Biophysics and Molecular Biology, vol.58, issue.3, pp.203-204, 1992.
DOI : 10.1016/0079-6107(92)90006-R

S. Olschwang, C. Bonaïti, J. Feingold, T. Frébourg, S. Grandjouan et al., Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas, Bull Cancer, vol.91, pp.303-315, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00427621

S. Parker, T. Tong, S. Bolden, and P. A. Wingo, Cancer statistics, 1997, CA: A Cancer Journal for Clinicians, vol.47, issue.1, pp.5-27, 1997.
DOI : 10.3322/canjclin.47.1.5

D. Parkin, F. Bray, J. Ferlay, and P. Pisani, Estimating the world cancer burden: Globocan 2000, International Journal of Cancer, vol.85, issue.2, pp.153-156, 2000.
DOI : 10.2105/AJPH.85.10.1356

J. Park, Y. Park, J. Wiijnen, and H. Vasen, Gene environnement interaction in hereditary nonpolyosis colorectal cancer with implications for diagnosis and genetic testing

G. Perkins, A. Lièvre, C. Ramacci, T. Méatchi, A. De-reynies et al., Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6, 2010.
DOI : 10.1002/ijc.25152

H. Prenen, D. Schutter, J. Jacobs, B. , D. Roock et al., PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer, Clinical Cancer Research, vol.15, issue.9, pp.3184-3188, 2009.
DOI : 10.1158/1078-0432.CCR-08-2961

R. Perez-soler, Can rash associated with HER1 /EGFR inhibittion be used as a marker of traetment outcome ? Oncology, pp.33-38, 2003.

R. Pérez-soler, J. Delord, A. Halpern, K. Kelly, J. Krueger et al., HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum, The Oncologist, vol.10, issue.5, pp.345-356, 2005.
DOI : 10.1634/theoncologist.10-5-345

C. Prin-mathieu, P. Aguilar, M. Béné, G. Faure, and M. Kolopp-sarda, Anticorps monoclonaux, anticorps th??rapeutiques, Revue Fran??aise des Laboratoires, vol.2003, issue.357, pp.31-39, 2003.
DOI : 10.1016/S0338-9898(03)90057-6

W. Samowitz, H. Albertsen, C. Sweeney, J. Herrick, B. Caan et al., Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer, JNCI: Journal of the National Cancer Institute, vol.98, issue.23, pp.1731-1738, 2006.
DOI : 10.1136/jmg.2004.020651

T. Schneider-merck, L. Van-bueren, J. Berger, S. Rossen, K. Van-berkel et al., Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage, The Journal of Immunology, vol.184, issue.1, pp.512-520, 2010.
DOI : 10.4049/jimmunol.0900847

S. Segaert and C. Van, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Annals of Oncology, vol.16, issue.9, pp.1425-1433, 2005.
DOI : 10.1007/978-3-642-59715-2

S. Siena, A. Sartore-bianchi, D. Nicolantonio, F. Balfour, J. Bardelli et al., Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor???Targeted Therapy in Metastatic Colorectal Cancer, JNCI: Journal of the National Cancer Institute, vol.27, issue.28, pp.1308-1324, 2009.
DOI : 10.1038/onc.2008.19

J. Souglakos, J. Philips, R. Wang, S. Marwah, M. Silver et al., Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, British Journal of Cancer, vol.62, issue.3, pp.465-472, 2009.
DOI : 10.1126/science.1145720

J. Spano and S. Vignot, Récepteurs de l'EGF dans les cancers colorectaux : ciblage et implication thérapeutique, Bull cancer, vol.94, pp.171-177, 2007.

J. Spano and . Qu, est-ce qu'une thérapie ciblée ? Le point de vue du clinicien, Bull cancer, vol.94, pp.111-115, 2007.

S. Thomas and J. Grandis, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation, Cancer Treatment Reviews, vol.30, issue.3, pp.255-268, 2004.
DOI : 10.1016/j.ctrv.2003.10.003

E. Van-cutsem, C. Köhne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

E. Van-cutsem, R. Mayer, and P. Gold, 279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin, European Journal of Cancer Supplements, vol.2, issue.8, pp.85-86, 2004.
DOI : 10.1016/S1359-6349(04)80287-8

B. Voldborg, L. Damstrup, M. Spang-thomsen, and H. Poulsen, Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials, Annals of Oncology, vol.8, issue.12, pp.1197-1206, 1997.
DOI : 10.1023/A:1008209720526